Courtney Flaherty

Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.

An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.

Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.